Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study
Langzeitwirkungen von Tofogliflozin auf die Nierenfunktion bei Patient:innen mit Typ-2-Diabetes: retrospektive multizentrische Studie
Journal of Diabetes Investigation · 2026-11 · 17 (11) · 1917-1926
DOI: 10.1111/jdi.70445 ↗Auf einen Blick
In einer retrospektiven Studie war der Rückgang der eGFR unter Tofogliflozin über 72 Monate langsamer als ohne Tofogliflozin. Auch nach Sensitivitätsanalyse blieben die Nierenbefunde konsistent.
Fragestellung
Welche Langzeitwirkung hat Tofogliflozin auf die Nierenfunktion bei Patient:innen mit Typ-2-Diabetes in der klinischen Praxis?
Methode
Retrospektive multizentrische Studie in 3 verbundenen Krankenhäusern; Patient:innen zwischen Januar 2015 und Mai 2024; IPTW und lineare Mixed-Effects-Modelle; Sensitivitätsanalyse mit multipler Imputation.
Ergebnisse
598 Teilnehmende (Tofogliflozin n=245; ohne Tofogliflozin n=353). eGFR-Änderung nach 72 Monaten: −4,51 vs. −10,64 mL/min/1,73 m2; Differenz 6,14 mL/min/1,73 m2; P<0,001.
Schlussfolgerung der Autor:innen
Real-World-Daten über 72 Monate deuteten darauf hin, dass Tofogliflozin den Rückgang der eGFR verlangsamen kann.
Kernaussagen
- eGFR-Rückgang unter Tofogliflozin langsamer als ohne Tofogliflozin
- 72-Monats-eGFR-Änderung: −4,51 vs. −10,64 mL/min/1,73 m2
- Unterschiede auch bei eGFR-Slope, HbA1c und Körpergewicht
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 19.09.2026. Verfasst von Natsuko Shinagawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Sodium-Glucose Transporter 2 Inhibitors, Glucosides. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kowa Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To investigate the long‐term renal effects of tofogliflozin, with the shortest half‐life among sodium–glucose cotransporter 2 inhibitors, in real‐world clinical practice. Materials and methods We retrospectively enrolled patients with type 2 diabetes mellitus treated at three affiliated hospitals between January 2015 and May 2024. The primary outcome was the change in estimated glomerular filtration rate from baseline to 72 months. After inverse probability of treatment weighting, linear mixed‐effects models were used to compare estimated glomerular filtration rate changes between the tofogliflozin and non‐tofogliflozin groups. As a sensitivity analysis, multiple imputation was performed to address missing baseline urinary albumin‐to‐creatinine ratio data. Secondary outcomes included estimated glomerular filtration rate slopes, changes in glycated hemoglobin and body weight at 72 months, and changes in urinary albumin‐to‐creatinine ratio at 48 months.
Results
Among 598 participants (tofogliflozin, n = 245; non‐tofogliflozin, n = 353), estimated glomerular filtration rate decline was significantly slower in the tofogliflozin group than in the non‐tofogliflozin group ( P < 0.001). At 72 months, the least squares mean estimated glomerular filtration rate change was −4.51 and −10.64 mL/min/1.73 m 2 , respectively (between‐group difference: 6.14 mL/min/1.73 m 2 ). Significant between‐group differences were observed in estimated glomerular filtration rate slope, glycated hemoglobin, and body weight, but not in urinary albumin‐to‐creatinine ratio. Renal findings were consistent in the multiple imputation sensitivity analysis.
Conclusions
Real‐world clinical data over 72 months suggested that tofogliflozin may slow estimated glomerular filtration rate decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Diabetes and Endocrinology, Kyoto Okamoto Memorial Hospital, Kumiyama, Japan.
- Department of Diabetology, Kameoka Municipal Hospital, Kyoto, Japan.
ORCID-Profile: Natsuko Shinagawa, Hiroshi Okada, Junya Hironaka, Shinta Yamamoto, Sayaka Kawai, Yuto Saijyo, Tomoya Katayama, Hanako Nakajima, Noriyuki Kitagawa, Masahide Hamaguchi
Förderung
- Kowa Company
Zitieren
APA
Shinagawa, N., Okada, H., Hironaka, J., Yamamoto, S., Yoneda, M., Kawai, S., Saijyo, Y., Katayama, T., Nakajima, H., Kishi, A., Kitagawa, N., Nakanishi, N., Hamaguchi, M., & Fukui, M. (2026). Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study. Journal of Diabetes Investigation, 17(11), 1917-1926. https://doi.org/10.1111/jdi.70445
Vancouver
Shinagawa N, Okada H, Hironaka J, Yamamoto S, Yoneda M, Kawai S, et al. Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study. Journal of Diabetes Investigation. 2026;17(11):1917-1926. doi:10.1111/jdi.70445
BibTeX
@article{Shinagawa2026,
author = {Shinagawa, Natsuko and Okada, Hiroshi and Hironaka, Junya and Yamamoto, Shinta and Yoneda, Mari and Kawai, Sayaka and Saijyo, Yuto and Katayama, Tomoya and Nakajima, Hanako and Kishi, Akio and Kitagawa, Noriyuki and Nakanishi, Naoko and Hamaguchi, Masahide and Fukui, Michiaki},
title = {Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study},
journal = {Journal of Diabetes Investigation},
year = {2026},
volume = {17},
number = {11},
pages = {1917--1926},
doi = {10.1111/jdi.70445}
}
EUVIMED